Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 18 recruiting now full pipeline

Generalized Anxiety Disorder: full-pipeline trial registry

18 of 49 indexed Generalized Anxiety Disorder trials are currently recruiting.

Corpus placement: #281 of 28,707 conditions by registered trial count.

49 US clinical trials · 18 currently recruiting · #281 of 28,707 conditions by registered trial count

Generalized Anxiety Disorder: 49 US clinical trials tracked, 18 recruiting.

Generalized Anxiety Disorder is the subject of 49 registered US clinical trials on ClinicalTrials.gov, 18 of them currently open to new participants. 12 are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most active sponsor is Massachusetts General Hospital, running 4 of these trials.

Enrollment posture brief

Registry condition generalized-anxiety-disorder

OPEN 18 | RECR 37% | LATE 12 | EARLY 9 | RANK #281 | SPON 4

Nearest open-share peer: Prostate Cancer (37% recruiting · 749 trials)

Diet, Healthy49%Duchenne Muscular Dystrophy44.9%Generalized Anxiety Diso (th…37%Chronic Disease36.7%Arthritis30.6%
Open-enrollment share among volume-matched conditions near Generalized Anxiety Disorder

Generalized Anxiety Disorder lists 18 open slots (37% of 49 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Generalized Anxiety Disorder on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Generalized Anxiety Disorder is recruiting below its size-band peers.

    18 of 49 indexed trials (36.7%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Generalized Anxiety Disorder trials is spread across many organizations.

    Massachusetts General Hospital accounts for 4 of 49 trials (8.2%). 35 distinct sponsors appear on at least one study for this condition label.

  3. Typical Generalized Anxiety Disorder enrolment sits around 130 participants.

    Median target enrolment is 130 among the 49 trials that report a genuine target (sentinel values excluded). 20 of those (40.8%) plan for fewer than 100 participants.

  4. Generalized Anxiety Disorder research is mostly interventional.

    47 interventional and 2 observational studies make up this index (95.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 11Phase 28Phase 35Phase 47

Open and recent trials

49 total, page 1 of 1

RECRUITING Phase 2 705 participants

Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder

Intra-Cellular Therapies

NCT06480383

RECRUITING NA 600 participants

CO2 Reactivity as a Biomarker of Non-Response to Exposure-Based Therapy

University of Texas at Austin

NCT05467683

RECRUITING Phase 2 570 participants

Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety Disorder

Intra-Cellular Therapies

NCT06701903

RECRUITING NA 501 participants

Implementing Team-Based Treatment for Pediatric Anxiety in Community Mental Health Settings

Bradley Hospital

NCT06934525

RECRUITING NA 300 participants

Brief Smartphone Treatment Study

Penn State University

NCT04846777

RECRUITING NA 256 participants

Validating an Autonomous Interactive Internet-Based Delivery of an Empirically Supported Cognitive Behavioral Therapy for Comorbidity

University of Minnesota

NCT05117255

RECRUITING Phase 3 250 participants

A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)

Definium Therapeutics US

NCT06809595

RECRUITING Phase 3 200 participants

A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Voyage)

Definium Therapeutics US

NCT06741228

RECRUITING Phase 2 180 participants

Search for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness

Brigham and Women's Hospital

NCT06376734

RECRUITING NA 180 participants

Respiratory Training in the Treatment of Transdiagnostic Pathological Anxiety

University of Texas at Austin

NCT05427708

RECRUITING NA 150 participants

MBSR Mechanisms in GAD

NYU Langone Health

NCT05064813

RECRUITING NA 139 participants

Internet-delivered Cognitive-Behavioral Therapy for Adolescents With Autism and Anxiety

Baylor College of Medicine

NCT06537128

RECRUITING NA 110 participants

Neurofeedback Enhanced Cognitive Reappraisal Training - Phase 4

University of Michigan

NCT06563310

RECRUITING NA 80 participants

Mindful Self-compassion for Anxiety and Depression: Impact of Delivery Method

Georgetown University

NCT07028216

RECRUITING NA 48 participants

Low-Intensity Focused Ultrasound Pulsation (LIFUP) for the Treatment of Generalized Anxiety Disorder (GAD)

University of California, Los Angeles

NCT04557891

RECRUITING NA 46 participants

Massage for GAD: Neuroimaging and Clinical Correlates of Response

University of Utah

NCT06506253

RECRUITING NA 40 participants

Mindful Self-Compassion for Anxiety Disorders and Depression

Georgetown University

NCT05671419

RECRUITING Phase 2 30 participants

Use of CBD in the Treatment of Anxiety

University of Florida

NCT06672666

ACTIVE NOT RECRUITING NA 375 participants

Patient-centered Treatment of Anxiety After Low-Risk Chest Pain in the Emergency Room

Indiana University

NCT04811521

ACTIVE NOT RECRUITING NA 250 participants

Outcomes of Cognitive Behavioral Therapy (CBT) Interventions Provided by Unlicensed Professionals

Massachusetts General Hospital

NCT01075672

ACTIVE NOT RECRUITING Phase 4 150 participants

Brain Stimulation & Generalized Anxiety Study

ProofPilot

NCT04751864

ACTIVE NOT RECRUITING NA 100 participants

Evaluation of Family-Based Behavioral Treatments for Youth With Anxiety and Obsessive-Compulsive Disorder

Baylor College of Medicine

NCT05967468

ACTIVE NOT RECRUITING Phase 2 36 participants

A Study of a N, N-dimethyltryptamine (DMT) Analog (CYB004) in Participants With Generalized Anxiety Disorder (GAD)

Cybin IRL Limited

NCT06051721

COMPLETED 1,431 participants

Evaluating the Effects of Stress in Pregnancy

Emory University

NCT00525226

COMPLETED Phase 3 440 participants

A 10-Week Study for Efficacy and Safety Study of Gabitril in the Treatment of Adults With Generalized Anxiety Disorder

Cephalon

NCT00236067

COMPLETED Phase 4 420 participants

Safety and Efficacy of Eszopiclone in Patients With Generalized Anxiety Disorder

Sumitomo Pharma America

NCT00235508

COMPLETED Phase 4 418 participants

Trial to Compare Time to Response in the Symptoms of Anxiety to Concomitant Treatment With Niravam™ and an SSRI or SNRI to Treatment With an SSRI or SNRI Alone in Subjects With Generalized Anxiety Disorder or Panic Disorder

UCB Pharma

NCT00266409

COMPLETED 338 participants

Feasibility and ML Training Investigation of the Senseye DT for Diagnosis of Adults with PTSD

Senseye

NCT05717439

COMPLETED NA 290 participants

Pragmatic Collaborative Care for Cardiac Inpatients With Depression or Anxiety

Massachusetts General Hospital

NCT03118752

COMPLETED Phase 2 260 participants

Study of Pexacerfont (BMS-562086) in the Treatment of Outpatients With Generalized Anxiety Disorder

Bristol-Myers Squibb

NCT00481325

COMPLETED NA 214 participants

Psychotherapy for Anxiety in Children With Autism Spectrum Disorder

University of South Florida

NCT02028247

COMPLETED Phase 3 180 participants

Long Term Chamomile Therapy for Anxiety

University of Pennsylvania

NCT01072344

COMPLETED NA 130 participants

CES for the Treatment of GAD in Young Adults

Electromedical Products International

NCT06124014

COMPLETED NA 121 participants

Approach-Avoidance Conflict-a Multi-level Predictor for Therapy Response

Laureate Institute for Brain Research

NCT02807480

COMPLETED NA 105 participants

Transdiagnostic Psychotherapy for Veterans With Mood and Anxiety Disorders

VA Office of Research and Development

NCT01947647

COMPLETED Phase 4 89 participants

Stress Reduction Techniques and Anxiety: Therapeutic and Neuroendocrine Effects

Massachusetts General Hospital

NCT01033851

COMPLETED NA 73 participants

Antidepressant Treatment Plus Cognitive Behavioral Therapy for Generalized Anxiety Disorder in Older Adults

Veterans Medical Research Foundation

NCT00601965

COMPLETED Phase 2 69 participants

Combined Treatment for Generalized Anxiety Disorder (GAD)

University of Pennsylvania

NCT00620776

COMPLETED NA 62 participants

Efficacy of Extended-release Quetiapine (Seroquel XR) as Adjunctive Therapy to Cognitive Behavioral Therapy in the Treat

Icahn School of Medicine at Mount Sinai

NCT01971203

COMPLETED Phase 4 61 participants

Chamomile Therapy for Generalized Anxiety

University of Pennsylvania

NCT00645983

COMPLETED Phase 4 60 participants

A Study of Risperidone Monotherapy in Bipolar Anxiety

University of South Florida

NCT00167479

COMPLETED Phase 4 49 participants

Ziprasidone in Bipolar Disorder With Comorbid Lifetime Panic or Generalized Anxiety Disorder(GAD)

VA Palo Alto Health Care System

NCT01172652

COMPLETED NA 45 participants

Effect of Mindfulness Meditation on Physiological Response to Unpredictable Stimuli

Georgetown University

NCT03206437

COMPLETED Phase 2 45 participants

Cognitive-Behavioral Treatment for Anxiety Disorders in Children With Autism Spectrum Disorders

University of South Florida

NCT01178385

COMPLETED NA 36 participants

Electronic Self-management Resource Training for Mental Health

Case Western Reserve University

NCT01304862

COMPLETED NA 30 participants

Exercise Training for the Treatment of Generalized Anxiety Disorder

University of Georgia

NCT00953654

COMPLETED NA 29 participants

Stress Reduction and Anxiety: Effects on the Function and Structure of the Brain

Massachusetts General Hospital

NCT01128309

COMPLETED Phase 3 17 participants

Memantine Treatment for Obsessive-compulsive Disorder and Generalized Anxiety Disorder

University of California, Los Angeles

NCT00674219

COMPLETED Phase 1 6 participants

An Open-label Study to Investigate the Absorption, Metabolism and Excretion of Radiolabeled PD 0332334 in Six Healthy Male Volunteers

Pfizer

NCT00537615

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 8
Phase 3 5
Phase 4 7

Named interventions

Most-linked intervention names on Generalized Anxiety Disorder records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
5 trials
Treatment as Usual Behavioral
3 trials
Placebo Other
3 trials
Cognitive behavioral therapy (CBT) Behavioral
2 trials
MM120 (LSD D-Tartrate) Drug
2 trials
Mindful Self-Compassion Behavioral
2 trials
ITI-1284 20 mg Drug
2 trials
ITI-1284 10 mg Drug
2 trials

US sites by state

Facility locations filed on Generalized Anxiety Disorder trials. A trial with sites in several states counts in each.

Florida 12 trials
California 12 trials
Massachusetts 10 trials
Georgia 9 trials
Texas 7 trials
Pennsylvania 6 trials
Ohio 5 trials
New York 5 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Generalized Anxiety Disorder page

49 registered trials, 18 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Generalized Anxiety Disorder condition card totals 49 registered trials; most-linked intervention Placebo; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.